Fas ligand expression in nodal non-Hodgkin's lymphoma

Modern Pathology

Volumn 11, Issue 4, 1998, Pages 369-375

  Müllauer, Leonhard ^a   Mosberger, Isabella ^a   Chott, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Fas; Fas ligand; Immune surveillance; Malignant lymphoma

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL LYMPHOMA;

B-LYMPHOCYTES; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, KI-1; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; MEMBRANE GLYCOPROTEINS; TUMOR CELLS, CULTURED;

EID: 0344404309     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
2. Nagata S, Golstein P. The Fas death factor. Science 1995;267: 1449-56.
3. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
4. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996;184:429-40.
5. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
6. Hahne M, Renno B, Schroeter M, Irmler M, French L, Bornand T, et al. Activated B cells express functional Fas ligand. Eur J Immunol 1996;26:721-4.
7. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-74.
8. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
9. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
10. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
11. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
12. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
13. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-12.
14. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
15. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
16. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas (Apo-1/ CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
17. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
18. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
20. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992;10:1457-63.
21. Kerstens HMJ, Poddighe P, Hanselaar AGJM. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem 1995;4:347-52.
22. Möller P, Henne C, Leithäuser F, Eichelmann A, Schmidt A, Brüderlein S, et al. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 1993;81:2067-75.
23. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-5.
24. Ponton A, Clement MV, Stamenkovic I. The CD95 (APO-1/ Fas) receptor activates NF-kB independently of its cytotoxic function. J Biol Chem 1996;271:8991-5.
25. Rensing-Ehl A, Hess S, Ziegler-Heitbrock HW, Rietmuller G, Engelmann H. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm 1995;45:161-74.
26. Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T. Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J Exp Med 1996;183:1377-88.
27. Yoshino T, Cao L, Nishiuchi R, Matsuo Y, Yamadori I, Kondo E, et al. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. Eur J Immunol 1995;25:2190-4.
28. Gregory CD, Tursz T, Edwards CF, Tetaud C, Talbot M, Caillou B, et al. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol 1987;139:313-8.
29. Owen-Schaub LB, Meterissian S, Ford RJ. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother 1993;14:234-41.
30. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, et al. Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 1994;145:330-7.
31. Nguyen PL, Harris NS, Ritz J, Robertson MJ. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996;148:847-53.
32. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997;97:409-17.
33. Falk MH, Trauth BC, Debatin KM, Klas C, Gregory CD, Rickinson AB, et al. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 1992;79:3300-6.
34. Nishiuchi R, Yoshino T, Matsuo Y, Sakuma I, Cao L, Seino Y, et al. The Fas antigen is detected on immature B cells and the representative cell lines show Fas-mediated apoptosis. Br J Haematol 1996;92:302-7.
35. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996;88:1375-82.
36. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997;90:12-20.
37. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
38. Kang S, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
39. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA, et al. The role of Fas in autoimmune diabetes. Cell 1997;89:17-24.